Navigation Links
New Pixantrone Data Presented at Meetings at American Society of Hematology Conference
Date:12/6/2010

SEATTLE, Dec. 6, 2010 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("the Company") (Nasdaq and MTA: CTIC) today announced new pixantrone end of study ("EOS") follow up results from the Company's pivotal phase III PIX301 trial, which results form the basis for the Company's recent Marketing Authorization Application (the "MAA") currently under review by the European Medicines Agency ("EMA").

The end-of-study results showed continued improvement in the trial's primary and secondary endpoints with increased statistical confidence around the endpoint results. At EOS, CR/CRu (Complete Response ("CR")/Complete Response unconfirmed) rate increased to 24% in the pixantrone arm compared to 7% among comparator recipients (p=0.009) while ORR (Overall Response Rate) increased to 40% versus 14% for comparator recipients (p=0.001). The median duration of CR/CRu was 9.6 months for the pixantrone group compared to 4.0 months for the comparator group. Pixantrone patients experienced a 40% reduction in the risk of death or progression over the two year study observation and follow up period compared to standard chemotherapy (p=0.005, HR=0.60) and a 21% reduction in the overall risk for dying (p= 0.25, HR =0.79).  The most common grade 3, 4 adverse event observed on the pixantrone arm was neutropenia in 41.2% of patients versus 19.4% on the comparator arm. However, the incidence of serious infections was comparable between arms. Deaths due to an adverse event were identical between both arms; there were more LVEF reductions in pixantrone arm, however only two were grade 3 and all were asymptomatic. The results were presented by Principal Investigator, Ruth Pettengell, M.D. of St. George's Hospital, University of London, the lead investigator for the phase III PIX301 EXTEND trial. "The end of study results strengthen the confidence and stability across the primary and secondary measures of efficacy," noted Dr. Pettengell.  "The magnitude of complete and durable
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. EMEA Validates Cell Therapeutics, Inc.s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP)
2. Cell Therapeutics, Inc. (CTI) Advances Pixantrone Filing Process in Europe; Submits Pediatric Investigation Plan (PIP)
3. Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
4. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
5. Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
6. Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
7. Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology
8. Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD
9. Investigational Data Presented for INTUNIV™ (guanfacine) Extended-Release Tablets When Coadministered With Stimulants Showed ADHD Symptom Improvement in Overall, Morning and Evening Assessments
10. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis plc ... pharmaceutical company, and Rhythm, a biopharmaceutical company, today announced ... acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., which ... the treatment of diabetic gastroparesis and other GI functional ... Phase 2 trial of relamorelin for the treatment of ...
(Date:10/22/2014)... 2014 WriteResult, LLC – a ... been working with a team of researchers from Yale ... Community Farming Collaborative to provide electronic questionnaire data collection ... study, which started in May, aims to evaluate the ... weekly exposure to and participation in urban agriculture to ...
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
(Date:10/20/2014)... October 20, 2014 The report ... Dispensing Systems, Packaging and Labeling Systems, Table-top Counters) ... - Global Forecasts & Trends to 2019” analyzes ... opportunities in North America, Europe, Asia-Pacific, and the ... market tables and 30 figures spread through 300 ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
... authorizations of $570.6 million, a sequential increase of 20.6 ... - Cash flow from operations of $61.6 million, resulting in $146.3 million ... cash flow from operations year-to-date ... of $0.32 within guidance range, WILMINGTON, N.C., Oct. 23 PPD, Inc. ...
... Oct. 23 Valeritas, LLC, a medical,technology company ... delivery solutions, announced today that John Timberlake,Executive Vice ... awarded,the distinguished Executive of Year award by the ... patients with diabetes in New,Jersey. "John,s continued ...
... (OTC Bulletin Board: CSBR), a development stage,biotechnology company, ... of the Head and Neck Cancer Research Division ... as Chairman of the Board,replacing James Martell who ... was appointed to serve on the Company,s Board ...
Cached Biology Technology:PPD Reports Third Quarter 2007 Financial Results; Announces Increase in Annual Cash Dividend From $0.12 to $0.40 Per Year 2PPD Reports Third Quarter 2007 Financial Results; Announces Increase in Annual Cash Dividend From $0.12 to $0.40 Per Year 3PPD Reports Third Quarter 2007 Financial Results; Announces Increase in Annual Cash Dividend From $0.12 to $0.40 Per Year 4PPD Reports Third Quarter 2007 Financial Results; Announces Increase in Annual Cash Dividend From $0.12 to $0.40 Per Year 5PPD Reports Third Quarter 2007 Financial Results; Announces Increase in Annual Cash Dividend From $0.12 to $0.40 Per Year 6John Timberlake, Valeritas' Executive Vice President and General Manager, Named Executive of the Year by the Diabetes Foundation 2John Timberlake, Valeritas' Executive Vice President and General Manager, Named Executive of the Year by the Diabetes Foundation 3Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc. 2Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc. 3Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc. 4
(Date:10/22/2014)... Inc. (NASDAQ: AWRE ), a leading supplier of ... third quarter ended September 30, 2014. Revenue for ... of 40% compared to $4.3 million in the same quarter ... was $4.1 million compared to $1.0 million in the third ... month period was primarily due to: i) a $1.0 million ...
(Date:10/18/2014)... group of 2,000 patients referred for evaluation of ... molecular diagnosis for 25 percent, including detection of ... mutations contributing to disease, according to a study ... being released to coincide with the American Society ... analyzes the exons or coding regions of thousands ...
(Date:10/17/2014)... German . ... in order to reproduce? And why are there two sexes ... latest issue of the research journal Molecular Human Reproduction ... Ramm from Bielefeld University Bielefeld has compiled this special issue ... a female to copulate with several males in quick succession ...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2
... Lee Lovering, Ph.D., School of Biosciences, University of ... Award for his seminal work on the structural ... and modify cell walls in bacteria. Natalie Strynadka, ... Lovering,s work: "his spectacular abilities in structural biology ...
... 2012) Aeras and the Infectious Disease Research Institute ... trial of IDRI,s novel tuberculosis vaccine candidate, ID93 + ... safety, tolerability and immunogenicity of the vaccine candidate in ... by Johnson County Clin-Trials in Lenexa, Kansas, in close ...
... risks posed to people who work with tiny fibres used ... Research into the health risks posed by nanofibres ... has pinpointed the lengths at which these fibres are ... from a range of materials including carbon, are about 1,000 ...
Cached Biology News:The American Society for Microbiology honors Andrew Lovering 2As TB grows more difficult to control, vaccine candidate to prevent disease enters clinical testing 2
... of modifications of Grace's medium were developed ... and 1970's. Many of these modifications were ... growth of cells derived from the cabbage ... known as TNM-FH. The medium when properly ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Mfr ...
... The LIC Duet™ T7•Tag ® ... lac operator, ribosome binding site (rbs), ... T7•Tag coding sequence. The T7•Tag is a ... useful for detection of the target protein ...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. Mfr Desig: ...
Biology Products: